Chief Executive Officer

Kamran Tahamtanzadeh, BA 

is an accomplished healthcare executive with over 25 years of global leadership experience in precision medicine, diagnostics, and digital health. As CEO, he brings a strong track record of scaling companies, securing strategic partnerships and funding, and commercializing innovative technologies across genomics, epigenetics, and cell therapy.

Darya Orlova, PhD

is an accomplished scientific leader with deep expertise in computational biology, immunology, and biophysics. As Chief Science Officer, she brings over 15 years of experience advancing drug target and biomarker discovery through systems biology, machine learning, and mechanistic modeling, with prior leadership roles at Genentech, Cell Signaling Technology, and Stanford University.

Behzad Mahdavi, PhD, MBA

is a visionary biopharma executive and innovation strategist with over 25 years of global experience driving patient-centric growth across biologics, cell and gene therapy, personalized medicine, and synthetic biology. Renowned for transforming breakthrough ideas into profitable strategies, he has held senior leadership roles at Lonza, Catalent Biopharma Solutions, and Ginkgo Bioworks.

As the author of Mastering Commercial Innovation and an active contributor to industry thought leadership, Dr. Mahdavi also serves on multiple boards and advisory panels for biotech and private equity & VC–backed companies. He brings deep expertise in commercialization, innovation management, and fundraising, combining scientific rigor with proven commercial leadership to help organizations deliver sustainable value and better outcomes for patients worldwide.

Hareem Maune, PhD

is an accomplished commercial leader with a strong technical background and has worked at global industry-leading organizations and startups. She has over 15 years of experience developing and bringing innovative products to market across multiple sectors including life sciences, medical devices, and synthetic biology. 

Notably, Dr. Maune helped launch the first spatial transcriptomics products in the market while at Veranome Bio (subsidiary of Applied Materials) and later at 10X Genomics, where she led the custom product business that expanded the accessibility of in-situ spatial transcriptomics across diverse applications. Her commercial and technical strategic initiatives have helped companies secure multi million dollars in funding and accelerated revenue growth.